Black Diamond Therapeutics

Yahoo Finance • 2 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership opportunities to advance pivotal developmen... Full story

Yahoo Finance • 3 months ago

Raymond James resumes coverage on Black Diamond stock with Outperform rating

Investing.com - Raymond James has resumed coverage on Black Diamond Therapeutics (NASDAQ:BDTX) with an Outperform rating and a price target of $11.00. Currently trading at $2.48, the stock has shown strong momentum with a 16% gain over t... Full story

Yahoo Finance • 3 months ago

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company’s Phase 1b FURTHER trial evaluating firmonertinib in first-line EGFR PACC-po... Full story

Yahoo Finance • 6 months ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS... Full story

Yahoo Finance • 7 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberration... Full story

Yahoo Finance • 7 months ago

NAYA Biosciences Announces Nomination of New Board Members

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing brea... Full story

Yahoo Finance • 2 years ago

With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to their trading actions 53% of the business is held by the top 6 shareholders Ownership research along with analyst for... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients wi... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update

Black Diamond Therapeutics Inc (NASDAQ:BDTX) reported Q3 2023 financial results, with a net loss of $23.0 million compared to $21.7 million in the same period in 2022. The company's cash, cash equivalents, and investments stood at $144.3 m... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecula... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients wi... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in pa... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in p... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC p... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of exi... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023; Dose Expansion cohorts expected to open in 2023FDA clearance of IND application fo... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

CAMBRIDGE, Mass. and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of ex... Full story

Yahoo Finance • 2 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

BDTX-1535 Phase 1 dose escalation ongoing in NSCLC harboring sensitizing EGFR mutations with or without CNS disease and recurrent GBM expressing EGFR alterations; Dose expansion cohorts expected to open in 2023 In preclinical tumor models,... Full story